抗血小板抗体在系统性红斑狼疮血小板减少患者中临床意义的研究

目的 明确抗血小板抗体在系统性红斑狼疮(SLE)血小板减少患者中的临床意义.方法 采用改良抗原捕获酶联免疫吸附试验(ELISA)法检测抗血小板抗体(抗GPⅡb/Ⅲa、GPⅠb/Ⅸ、GPⅠa/Ⅱa、GPⅣ抗体),分别比较治疗前SLE血小板减少与SLE非血小板减少患者抗血小板抗体的阳性率、SLE血小板减少患者治疗前后抗血小板抗体的阳性率、SLE血小板减少治疗前患者病情与抗血小板抗体的关联性.统计方法采用秩和检验和x2检验.结果 治疗前SLE血小板减少组抗GPⅡb/Ⅲa抗体、抗GP Ⅰb,Ⅸ抗体阳性率分别为50%、67%.非血小板减少组阳性率分别为11%、28%,2组间阳性率差异有统计学意义(P＜0.05);治疗后SLE血小板减少组抗GPⅡb/Ⅲa抗体、抗GP Ⅰb/Ⅸ抗体阳性率分别为6%、28%,较治疗前显著降低(P＜0.05);SLE血小板减少组治疗前抗GPⅡb/Ⅲa抗体、抗GP Ⅰb/Ⅸ抗体之间显著关联,该2种抗体均与SLEDAI评分有显著关联性,与抗核抗体、抗双链DNA(dsDNA)抗体、抗中性粒细胞胞质抗体(ANCA)则无显著关联;各组间未检测出抗GPⅣ和GPⅠa/Ⅱa抗体.结论 抗GPⅡb/Ⅲa、GPⅠb/Ⅸ抗体在病情活动SLE血小板减少患者中表达显著升高,与SLE血小板减少病情发生发展和转归相关.

Abstract：

Objective To evaluate the clinical significance of antiplatelet antibody in patients with systemic lupus erythematosus complicated with thrombocytopenia.Methods Antiplatelet antibody (anti-GP Ⅱb/Ⅲa antibody, anti-GP Ⅰb/Ⅸ antibody, anti-GP Ⅰa/Ⅱ a antibody, anti-GP Ⅳ antibody) were detected by modified antigen capture ELISA. The positive rate of antiplatelet antibody between SLE complicated with thrombocytopenia group and without thrombocytopenia group before therapy were compared,and the positive rate of antiplatelet antibody before therapy and after therapy in SLE complicated with thrombocytopenia were compared,and the relevance between antiplatelet antibody and conditions in SLE complicated with thrombocytopenia were analyzed. Rank test and Chi square test were used for statistical analysis. Results The positive rate of anti-GP Ⅱb/Ⅲa antibody and anti-GP Ⅰb/Ⅸ antibody in SLE complicated with thrombocytopenia group before therapy was 50% and 67% respectively, however,the positive rate in SLE without thrombocytopenia group before therapy was 11% and 28% respectively,there was significant difference between the two groups (P＜0.05) and the positive rate of anti-GP Ⅱb/Ⅲa antibody and anti-GP Ⅰb/Ⅸ antibody in SLE complicated with thrombocytopenia group after therapy was 6% and 28% respectively, which was significantly lower than those before therapy (P＜0.05). In SLE complicated with thrombocytopenia group before therapy, there was significant relevance between anti-GP Ⅱb/Ⅲ a antibody and anti-GPb/Ⅸ antibody, and there was significant relevance between these two antibodies and SLEDAI score,but no significant relevance between these two antibodies and ANA,dsDNA, ANCA. Neither anti-GPⅣ antibody nor anti-GP Ⅰ a/Ⅱ a antibody was detected in patients of this study. Conclusion The positive rate of antiplatelet antibody (anti-GP Ⅱb/Ⅲ a antibody, anti-GP Ⅰb/Ⅸ antibody) is significantly higher in patients with active systemic lupus erythematosus complicated with thrombocytopenia,and these two antibodies are significantly associated with clinical outcomes.

Study on clinical significance of antiplatelet antibody in patients with systemic lupus erythematosus complicated with thrombocytopenia

Objective To evaluate the clinical significance of antiplatelet antibody in patients with systemic lupus erythematosus complicated with thrombocytopenia.Methods Antiplatelet antibody (anti-GP Ⅱb/Ⅲa antibody, anti-GP Ⅰb/Ⅸ antibody, anti-GP Ⅰa/Ⅱ a antibody, anti-GP Ⅳ antibody) were detected by modified antigen capture ELISA. The positive rate of antiplatelet antibody between SLE complicated with thrombocytopenia group and without thrombocytopenia group before therapy were compared,and the positive rate of antiplatelet antibody before therapy and after therapy in SLE complicated with thrombocytopenia were compared,and the relevance between antiplatelet antibody and conditions in SLE complicated with thrombocytopenia were analyzed. Rank test and Chi square test were used for statistical analysis. Results The positive rate of anti-GP Ⅱb/Ⅲa antibody and anti-GP Ⅰb/Ⅸ antibody in SLE complicated with thrombocytopenia group before therapy was 50% and 67% respectively, however,the positive rate in SLE without thrombocytopenia group before therapy was 11% and 28% respectively,there was significant difference between the two groups (P＜0.05) and the positive rate of anti-GP Ⅱb/Ⅲa antibody and anti-GP Ⅰb/Ⅸ antibody in SLE complicated with thrombocytopenia group after therapy was 6% and 28% respectively, which was significantly lower than those before therapy (P＜0.05). In SLE complicated with thrombocytopenia group before therapy, there was significant relevance between anti-GP Ⅱb/Ⅲ a antibody and anti-GPb/Ⅸ antibody, and there was significant relevance between these two antibodies and SLEDAI score,but no significant relevance between these two antibodies and ANA,dsDNA, ANCA. Neither anti-GPⅣ antibody nor anti-GP Ⅰ a/Ⅱ a antibody was detected in patients of this study. Conclusion The positive rate of antiplatelet antibody (anti-GP Ⅱb/Ⅲ a antibody, anti-GP Ⅰb/Ⅸ antibody) is significantly higher in patients with active systemic lupus erythematosus complicated with thrombocytopenia,and these two antibodies are significantly associated with clinical outcomes.